On Feb. 7, the U.S. Food and Drug Administration announced that drug interactions between the hepatitis C virus protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medications when they are used in combination. Read more.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder